Claritas Pharmaceuticals
Pioneering the development of next-generation cannabinoid therapeutics with a focus on creating a new class of proprietary CBD treatments.
Pioneering the development of next-generation cannabinoid therapeutics with a focus on creating a new class of proprietary CBD treatments.
Claritas Pharmaceuticals is a biotechnology company which is pioneering the development of next-generation cannabinoid therapeutics, with a primary focus on creating a new class of proprietary CBD treatments. The company, founded in 2004, operates within the Biotechnology and Health Care industries. In its latest funding round on 12 January 2022, Alumina Partners led a $5.00M Private Equity Round investment in the company. Claritas Pharmaceuticals, under its subsidiary Kalytera, is at the forefront of advancing a new generation of cannabinoid-based medications, specifically concentrating on the development of exclusive cannabidiol (“CBD”) therapeutics.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Private Equity Round | $5.00M | 1 | Alumina Partners | 12 Jan 2022 |
| Post-IPO Debt | $930.00K | 1 | Obsidian Global Partners | 19 Oct 2021 |
| Post-IPO Equity | $1.62M | - | 14 May 2019 | |
| Post-IPO Equity | $6.76M | - | 26 Apr 2019 | |
| Post-IPO Equity | $4.30M | - | 08 Aug 2018 |
No recent news or press coverage available for Claritas Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
-Farrell-logo.jpg){kind=logo}
